Felisecto Plus

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

selamectin, sarolaner

Available from:

Zoetis Belgium SA

ATC code:

QP54AA55

INN (International Name):

selamectin, sarolaner

Therapeutic group:

Cats

Therapeutic area:

Antiparasitic products, insecticides and repellents

Therapeutic indications:

For cats with, or at risk from, mixed parasitic infestations by ticks and fleas, lice, mites, gastrointestinal nematodes or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks and one or more of the other target parasites is indicated at the same time.

Product summary:

Revision: 2

Authorization status:

Authorised

Authorization date:

2019-04-26

Patient Information leaflet

                                18
B. PACKAGE LEAFLET
19
PACKAGE LEAFLET:
FELISECTO PLUS 15 MG/2.5 MG SPOT-ON SOLUTION FOR CATS ≤2.5 KG
FELISECTO PLUS 30 MG/5 MG SPOT-ON SOLUTION FOR CATS >2.5–5 KG
FELISECTO PLUS 60 MG/10 MG SPOT-ON SOLUTION FOR CATS >5–10 KG
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIUM
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Felisecto Plus 15 mg/2.5 mg spot-on solution for cats ≤2.5 kg
Felisecto Plus 30 mg/5 mg spot-on solution for cats >2.5–5 kg
Felisecto Plus 60 mg/10 mg spot-on solution for cats >5–10 kg
selamectin/sarolaner
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Each unit dose (pipette) delivers:
ACTIVE SUBSTANCES:
Felisecto Plus
spot-on solution
Total volume of
unit dose (ml)
selamectin (mg)
sarolaner (mg)
Cats ≤2.5 kg
0.25
15
2.5
Cats >2.5–5 kg
0.5
30
5
Cats >5–10 kg
1
60
10
EXCIPIENTS:
0.2 mg/ml butylated hydroxytoluene.
Spot-on solution.
Clear, colourless to yellow solution.
4.
INDICATION(S)
For cats with, or at risk from, mixed parasitic infestations by ticks
and fleas, lice, mites,
gastrointestinal nematodes or heartworm. The veterinary medicinal
product is exclusively indicated
when use against ticks and one or more of the other target parasites
is indicated at the same time.
ECTOPARASITES:
-
For the treatment and prevention of flea infestations (
_Ctenocephalides_
spp.). The veterinary
medicinal product has immediate and persistent flea killing activity
against new infestations for
5 weeks. The product kills adult fleas before they lay eggs for 5
weeks. Through its ovicidal and
20
larvicidal action, the veterinary medicinal product may aid in the
control of existing
environmental flea infestations in areas to which the animal has
access.
-
The product can be used as part of a treatment strategy for flea
allergy dermatitis (F
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Felisecto Plus 15 mg/2.5 mg spot-on solution for cats ≤2.5 kg
Felisecto Plus 30 mg/5 mg spot-on solution for cats >2.5–5 kg
Felisecto Plus 60 mg/10 mg spot-on solution for cats >5–10 kg
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each unit dose (pipette) delivers:
ACTIVE SUBSTANCES:
Felisecto Plus
spot-on solution
Pipette content
(ml)
selamectin (mg)
sarolaner (mg)
Cats ≤2.5 kg
0.25
15
2.5
Cats >2.5–5 kg
0.5
30
5
Cats >5–10 kg
1
60
10
EXCIPIENTS:
0.2 mg/ml butylated hydroxytoluene.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
Clear, colourless to yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For cats with, or at risk from, mixed parasitic infestations by ticks
and fleas, lice, mites,
gastrointestinal nematodes or heartworm. The veterinary medicinal
product is exclusively indicated
when use against ticks and one or more of the other target parasites
is indicated at the same time.
ECTOPARASITES:
-
For the treatment and prevention of flea infestations (
_Ctenocephalides_
spp.). The veterinary
medicinal product has immediate and persistent flea killing activity
against new infestations for
5 weeks. The product kills adult fleas before they lay eggs for 5
weeks. Through its ovicidal and
larvicidal action, the veterinary medicinal product may aid in the
control of existing
environmental flea infestations in areas to which the animal has
access.
-
The product can be used as part of a treatment strategy for flea
allergy dermatitis (FAD).
-
Treatment of tick infestations. The veterinary medicinal product has
immediate and persistent
acaricidal effect for 5 weeks against
_Ixodes ricinus _
and
_Ixodes hexagonus_
, and 4 weeks against
_Dermacentor reticulatus _
and
_ Rhipicephalus sanguineus_
.
3
-
Treatment of ear mites (
_Otodectes cynotis_
).
-
Treatment of biting lice infestations
_(Felicola subrostra
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-06-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-06-2021
Public Assessment Report Public Assessment Report Bulgarian 14-05-2019
Patient Information leaflet Patient Information leaflet Spanish 15-06-2021
Public Assessment Report Public Assessment Report Spanish 14-05-2019
Patient Information leaflet Patient Information leaflet Czech 15-06-2021
Public Assessment Report Public Assessment Report Czech 14-05-2019
Patient Information leaflet Patient Information leaflet Danish 15-06-2021
Public Assessment Report Public Assessment Report Danish 14-05-2019
Patient Information leaflet Patient Information leaflet German 15-06-2021
Public Assessment Report Public Assessment Report German 14-05-2019
Patient Information leaflet Patient Information leaflet Estonian 15-06-2021
Public Assessment Report Public Assessment Report Estonian 14-05-2019
Patient Information leaflet Patient Information leaflet Greek 15-06-2021
Public Assessment Report Public Assessment Report Greek 14-05-2019
Patient Information leaflet Patient Information leaflet French 15-06-2021
Public Assessment Report Public Assessment Report French 14-05-2019
Patient Information leaflet Patient Information leaflet Italian 15-06-2021
Public Assessment Report Public Assessment Report Italian 14-05-2019
Patient Information leaflet Patient Information leaflet Latvian 15-06-2021
Public Assessment Report Public Assessment Report Latvian 14-05-2019
Patient Information leaflet Patient Information leaflet Lithuanian 15-06-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-06-2021
Public Assessment Report Public Assessment Report Lithuanian 14-05-2019
Patient Information leaflet Patient Information leaflet Hungarian 15-06-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 15-06-2021
Public Assessment Report Public Assessment Report Hungarian 14-05-2019
Patient Information leaflet Patient Information leaflet Maltese 15-06-2021
Public Assessment Report Public Assessment Report Maltese 14-05-2019
Patient Information leaflet Patient Information leaflet Dutch 15-06-2021
Public Assessment Report Public Assessment Report Dutch 14-05-2019
Patient Information leaflet Patient Information leaflet Polish 15-06-2021
Public Assessment Report Public Assessment Report Polish 14-05-2019
Patient Information leaflet Patient Information leaflet Portuguese 15-06-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 15-06-2021
Public Assessment Report Public Assessment Report Portuguese 14-05-2019
Patient Information leaflet Patient Information leaflet Romanian 15-06-2021
Public Assessment Report Public Assessment Report Romanian 14-05-2019
Patient Information leaflet Patient Information leaflet Slovak 15-06-2021
Public Assessment Report Public Assessment Report Slovak 14-05-2019
Patient Information leaflet Patient Information leaflet Slovenian 15-06-2021
Summary of Product characteristics Summary of Product characteristics Slovenian 15-06-2021
Public Assessment Report Public Assessment Report Slovenian 14-05-2019
Patient Information leaflet Patient Information leaflet Finnish 15-06-2021
Public Assessment Report Public Assessment Report Finnish 14-05-2019
Patient Information leaflet Patient Information leaflet Swedish 15-06-2021
Public Assessment Report Public Assessment Report Swedish 14-05-2019
Patient Information leaflet Patient Information leaflet Norwegian 15-06-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 15-06-2021
Patient Information leaflet Patient Information leaflet Icelandic 15-06-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 15-06-2021
Patient Information leaflet Patient Information leaflet Croatian 15-06-2021
Public Assessment Report Public Assessment Report Croatian 14-05-2019

Search alerts related to this product

View documents history